Status:
TERMINATED
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Lead Sponsor:
University Hospital of Mont-Godinne
Collaborating Sponsors:
Université Catholique de Louvain
Teva Pharmaceuticals USA
Conditions:
Relapsing Remitting Multiple Sclerosis
Secondary-progressive Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
Detailed Description
tDCS will be used in a sham-controlled, double-blind, randomized, cross-over control trial in MS patients suffering from cognitive impairments and/or motor deficits. After informed consent and recruit...
Eligibility Criteria
Inclusion
- MS patients with relapsing remitting MS/secondary progression MS (based on the 2010 revised McDonald criteria)
- Cognitive deficits
- Motor deficits
Exclusion
- contraindication to tDCS (seizure or epilepsy, metal in the head, …)
- major psychiatric conditions or major depression
- coexisting instable medical condition
- substance or alcohol abuse
- regular intake of drug that strongly modulate brain excitability
- major sequels from MS preventing participation in the study
- pregnancy
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 8 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02266121
Start Date
October 1 2014
End Date
May 8 2023
Last Update
May 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurology, CHU Dinant Godinne UcL Namur
Yvoir, Namur, Belgium, B-5530